The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT to patients. In addition, non-clinical stakeholders introduce interests and agendas that may differ from those of clinicians. This article reviews the history of how psychedelics were initially outlawed and then introduces research questions that will help to fill these gaps in knowledge.
Get full access to this article
View all access options for this article.
References
1.
ReiffCM, RichmanEE, NemeroffCB, et al.Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry, 2020; 177(5):391–410.
2.
BodieA.Off Label Use of Prescription Drugs, Congressional Research Services Report R45792; February 23, 2021. Available from: https://sgp.fas.org/crs/misc/R45792.pdf [Last accessed: January13, 2023].
3.
The Federal Register. Withdrawal of Approval of an Application or Abbreviated Application 21 CFR 314.150; April 28, 1993. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.150 [Last accessed: January20, 2023].
4.
BelouinSJ, HenningfieldJE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 2018; 142:7–19; doi: 10.1016/j.neuropharm.2018.02.018
NicholsDE.Entactogens: How the name for a novel class of psychoactive agents originated. Front Psychiatry, 2022; 13:863088; doi: 10.3389/fpsyt.2022.863088
7.
YehudaR, LeptowLA, BonnanoPA, et al.Neurobiology of Mental Illness, 6th ed. In: Psychedelic Drugs as Treatment Agents (in press). (CharneyDS, NestlerEJ. eds.) Chapter 74. Oxford University Press: Oxford, United Kingdom; In Press.
8.
DoblinR.Multidisciplinary Association for Psychedelics Studies: Interview with Rick Doblin, Psychedelic Pioneer and Founder of MAPS (Video); 2014. Available from: https://maps.org/2014/07/01/interview-with-rick-doblin-psychedelic-pioneer-founder-of-maps/ [Last accessed: January5, 2023].
RothlinE.Pharmacology of lysergic acid diethylamide and some of its related CompoundS. J Pharm Pharmacol, 1957; 9(1):569–587; doi: 10.1111/j.2042-7158.1957.tb12312.x
13.
BakerED.The use of lysergic acid diethylamide (LSD) in psychotherapy. Can Med Assoc J, 1964; 91(23):1200–1202.
14.
AndersenKAA, Carhart-HarrisR, NuttDJ, et al.Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand, 2021; 143(2):101–118; doi: 10.1111/acps.13249
15.
DaemmrichA.A tale of two experts: Thalidomide and political engagement in the United States and West Germany. Soc Hist Med, 2002; 15(1):137–158; doi: 10.1093/shm/15.1.137
16.
ShorterE.Before Prozac:. The Troubled History of Mood Disorders in Psychiatry. Oxford University Press: Oxford, United Kingdom; 2009.
17.
Food and Drug Administration. Drug Efficacy Safety Investigation, Silver Spring, MD; 2022 Available from: https://www.fda.gov/drugs/enforcement-activities-fda/drug-efficacy-study-implementation-desi [Last accessed: January5, 2023].
18.
LearyT.The Psychedelic Experience; A Manual Based on the Tibetan Book of the Dead. Citadel Press: New York, NY; 1968.
19.
WolfeT.The Electric Kool-Aid Acid Test. Picador: New York NY; 1968.
20.
Gissen-StanleyR, DavisT.Owsley and Me: My LSD Family. Monkfish Book Publishing Company: Rhinebeck, NY; 2012.
21.
GrimesW. Nicholas Sand, Chemist Who Sought to Bring LSD to the World, Dies at 75, New York Times. May 14, 2017. Available from: https://www.nytimes.com/2017/05/12/us/nicholas-sand-chemist-who-sought-to-bring-lsd-to-the-world-dies-at-75.html
22.
ABC Australia (Director), The Final Days of TimothyLeary, High Priest of LSD (film). Ultimo, Australia; 1996. Available from: https://www.journeyman.tv/film_documents/235/transcript/ [Last accessed: January5, 2023].
23.
HartogsohnI.American Trip: Set, Setting, and the Psychedelic Experience in the 20th Century. MIT Press: Cambridge, MA; 2020.
24.
ManginiM.A Short, Strange Trip: LSD Politics, Publicity, and Mythology From Discovery to Criminalization. In: Handbook of Medical Hallucinogens. (Grob CS, Grigsby J. eds) Guilford Press: New York, NY; 2021; pp. 68–94.
25.
Office of the Law Revision Council United States Code. An Act to Amend the Federal Food, Drug, and Cosmetic Act to Increase the Penalties [H. R. I4096] for Unlawful Acts Involving Lysergic Acid Diethylamide (LSD) and Other Depressant and Stimulant Drugs, and for Other Purposes. Public Law 90-639; 1968. Available from: https://uscode.house.gov/statutes/pl/90/638.pdf [Last accessed: February26, 2023].
26.
Drug Enforcement Administration. Controlled Substance Act. Washington, DC; 1970. Available from: https://www.dea.gov/drug-information/csa [Last accessed: January5, 2023].
27.
InouyeD, GoldwaterB. Project MKULTRA, the CIA's Program of Research in Behavioral Modification, Joint Hearing Before the Select Committee on Intelligence, 95th Congress; August 3, 1977. Available from: https://www.intelligence.senate.gov/sites/default/files/hearings/95mkultra.pdf [Last accessed: January14, 2023].
28.
RicaurteGA, YuanJ, HatzidimitriouG, et al.Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“Ecstasy”). Science 2002 (5590):2260–2263. [10.1126/science.1074501] (Retraction published Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Science, 2003; 301(5639):1479). [doi: 10.1126/science.301.5639.1479b].
29.
ParrottAC.Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology, 2009; 60(3–4):148–158; doi: 10.1159/000253551
30.
BaumannMH, RothmanRB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol, 2009; 88:257–296; doi: 10.1016/S0074-7742(09)88010-0
31.
StrassmanRJ, QuallsCR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry, 1994; 51(2):85–97; doi: 10.1001/archpsyc.1994.03950020009001
32.
SessaB.The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society. Muswell Hill Press: London; 2013.
33.
GriffithsRR, RichardsWA, McCannU, et al.Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 2006; 187(3):268–292; doi: 10.1007/s00213-006-0457-5
34.
MorenoFA, WiegandCB, TaitanoEK, et al.Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 2006; 67(11):1735–1740; doi: 10.4088/jcp.v67n1110
35.
MitchellJM, BogenschutzM, LiliensteinA, et al.MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med, 2021; 27(6):1025–1033; doi: 10.1038/s41591-021-01336-3
36.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-dose psilocybin for a treatment-resistant episode of major depression. NEJM, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
37.
KupferschmidtK.All clear on the decisive trial of ecstasy for PTSD patients. Science 2017; doi: 10.1126/science.aap7739. Available from: https://www.science.org/content/article/all-clear-decisive-trial-ecstasy-ptsd-patients [Last accessed: February3, 2023].
38.
EisensteinM.The psychedelic escape from depression. Nature, 2022; 609(7929):S87–S89.
39.
Food and Drug Administration, Breakthrough Therapy, Silver Spring, MD; 2018. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy [Last accessed: January5, 2023].
40.
CheungA, SacksD, DewaCS, et al.Pediatric prescribing practices and the FDA Black-box warning on antidepressants. J Dev Behav Pediatr, 2008; 29(3):213–215; doi: 10.1097/DBP.0b013e31817bd7c9
41.
YehudaR.Treating Trauma Survivors with PTSD (1st ed.) (Yehuda R. ed.) American Psychiatric Publishing: Washington, DC; 2002; pp. IX–XVI.
42.
SchnurrPP, ChardKM, RuzekJI, et al.Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US Veterans: A randomized clinical trial. JAMA Netw Open, 2022; 5(1):e2136921; doi: 10.1001/jamanetworkopen.2021.36921
43.
GreenwayKT, GarelN, JeromeL, et al.Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol, 2020; 13(6):655–670; doi: 10.1080/17512433.2020.1772054
44.
JohnsonM, RichardsW, GriffithsR. Human hallucinogen research: guidelines for safety. J Psychopharmacol, 2008; 22(6):603–620; doi: 10.1177/0269881108093587
45.
McNameeS, DevenotN, BuissonM. Studying harms is key to improving psychedelic-assisted therapy-participants call for changes to research landscape. JAMA Psychiatry, 2023; 80(5):411–412; doi: 10.1001/jamapsychiatry.2023.0099
46.
NiauraR.Varenicline and suicide: Reconsidered and reconciled. Nicotine Tobacco Res, 2016; 18(1):1; doi: 10.1093/ntr/ntv247
47.
KaneSP.Varenicline, ClinCalc DrugStats Database, Version 2022.08. ClinCalc; 2022. Available from: https://clincalc.com/DrugStats/Drugs/Varenicline [Last accessed: November21, 2022].
48.
HullTD, MalgaroliM, GazzaleyA, et al.At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. J Affect Disord, 2022; 314:59–67; doi: 10.1016/j.jad.2022.07.004
49.
WilkinsonST, SanacoraG. At-home ketamine; still a lot to learn. J Affect Disord, 2022; 318:150–151; doi: 10.1016/j.jad.2022.08.090
50.
MichaelsTI, PurdonJ, CollinsA, et al.Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry, 2018; 18(1):245; doi: 10.1186/s12888-018-1824-6
51.
KaryT.Psychedelics Can Treat PTSD, So Should They Be Given to Soldiers? Bloomberg; November 7, 2022. Available from: https://www.bloomberg.com/news/newsletters/2022-11-07/psychedelics-for-the-military-debate-grows-over-treatments-for-ptsd [Last accessed: January13, 2023].
52.
KesslerRC, SonnegaA, BrometE, et al.Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 1995; 52(12):1048–1060; doi: 10.1001/archpsyc.1995.03950240066012
53.
FordJD, CourtoisCA. Complex PTSD and borderline personality disorder. Borderline Personality Disorder Emot Dysregul, 2021; 8(1):16; doi: 10.1186/s40479-021-00155-9
54.
GrofS.LSD Psychotherapy. MAPS Press: Santa Cruz, CA; 1980.
55.
YadenDB, EarpD, GraziosiM, et al.Psychedelics and psychotherapy: Cognitive-behavioral approaches as default. Front Psychol, 2022; 13:873279; doi: 10.3389/fpsyg.2022.873279
PolitoV, LiknaitzkyP. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neurosci Biobehav Rev, 2022; 139:104706; doi: 10.1016/j.neubiorev.2022.104706
58.
PhelpsJ, HenryJ.Foundations for Training Psychedelic Therapists. In: Disruptive Psychopharmacology. (Barrett FS, Preller KH. eds.) Current Topics in Behavioral Neurosciences, Vol. 56. Springer: Cham, Switzerland; 2021; pp. 94–106
59.
MarseilleE, BertozziS, KahnJG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry, 2022; 13:1025726; doi: 10.3389/fpsyt.2022.1025726
60.
Study Comparing Two Versus Three Active MDMA-Assisted Sessions inU.S.Military Veterans With Chronic PTSD (MPVA6), NCT04784143. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04784143 [Last accessed: July15, 2023].
61.
AndersonBT, DanforthA, DaroffPR, et al.Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine, 2020; 27:100538; doi: 10.1016/j.eclinm.2020.100538
62.
BathjeGJ, MajeskiE, KudoworM. Psychedelic integration: An analysis of the concept and its practice. Front Psychol, 2022; 13:824077; doi: 10.3389/fpsyg.2022.824077
63.
Carhart-HarrisR, GiribaldiB, WattsR, et al.Trial of psilocybin versus escitalopram for depression. NEJM, 2021; 384(15):1402–1411; doi: 10.1056/NEJMoa2032994
64.
WeissB, ErritzoeD, GiribaldiB, et al.A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. J Psychopharmacol (Oxford), 2023; 37(7):717–732; doi: 10.1177/02698811231167848
65.
MarseilleE, MitchellJM, KahnJG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a Phase 3 trial. PLoS One, 2022; 17(2):e0263252; doi: 10.1371/journal.pone.0263252
66.
ShulginA, ShulginA.PIHKAL: Phenylethylamines I Have Known and Loved. Transform Press: Berkeley, CA; 1991
67.
MarksM.The varieties of psychedelic law. Neuropharmacology, 2022; 226:109399; doi: 10.1016/j.neuropharm.2022.109399
68.
PleetMM, WhiteJ, ZamariaJA, et al.Reducing the harms of nonclinical psychedelics use through a peer-support telephone helpline. Psyched Med, 2023; 1(2):69–73; doi: 10.1089/psymed.2022.0017
69.
Oregon Health Authority (ND) Oregon Psilocybin Services. Available from: https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx [Last accessed: January5, 2023].
70.
Psychedelic Alpha. Psychedelic Legalization and Legislation Tracker Psychedelic Alpha; 2023. Available from: https://psychedelicalpha.com/data/psychedelic-laws [Last accessed: January19, 2023].
71.
Bloomberg News, Psychedelic Therapeutics Market Worth $ 8.31 Billion by 2028; 2022. Available from: https://www.bloomberg.com/press-releases/2022-07-18/psychedelic-therapeutics-market-worth-8-31-billion-by-2028-exclusive-report-by-insightace-analytic [Last accessed: January5, 2023].
72.
PollanM.How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Penguin Books: New York, NY; 2019.
73.
NorthH.Sophrosyne: Self-Knowledge and Self-Restraint in Greek Literature. Cornell University Press: Ithaca, NY; 1966.
74.
MontaigneM.Of Experience. In: Michele de Montaigne—The Complete Essays (Screech MA, ed. and Trans). Penguin Classics: London;. 1588.
